Cellbion셀비온
308430 · KOSDAQ · ₩308430 · 셀비온
₩11,940▲ ₩620 (5.48%)End-of-day · Oct 28, 2026 · End-of-day prices.
Filings
- Major management matter relevant to investors투자판단관련주요경영사항(임상시험계획승인신청등결정) (전이성 거세저항성 전립선암 환자에서 Lutetium(177Lu) DGUL(포큐보타이드 사테트라세탄)의 유효성 및 안전성을 평가하기 위한 다기관, 공개, 무작위배정, 제 3상 임상시험 계획 승인)Sep 29, 2026Open on DART
- Half-year report (Jun 2026)반기보고서 (2026.06)Aug 13, 2026Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항(임상시험계획승인신청) (전이성 거세저항성 전립선암 환자에서 Lutetium(177Lu) DGUL(포큐보타이드 사테트라세탄)의 유효성 및 안전성을 평가하기 위한 다기관, 공개, 무작위배정, 제 3상 임상시험 계획 승인신청)Jun 30, 2026Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서May 15, 2026Open on DART
- Quarterly report (Mar 2026)분기보고서 (2026.03)May 14, 2026Open on DART
- Results of Securities Issuance (Voluntary Disclosure) (Third-Party Allotment – Convertible Preferred Shares)증권발행결과(자율공시) (제3자배정-전환우선주)Apr 23, 2026Open on DART
- Securities Issuance Results (Voluntary Disclosure) (3rd Convertible Bond Issue)증권발행결과(자율공시) (제3회차 CB)Apr 23, 2026Open on DART
- Amended: Rights offering (paid-in capital increase) decision[기재정정]주요사항보고서(유상증자결정)Apr 22, 2026Open on DART
- Amended: Convertible bond issue decision[기재정정]주요사항보고서(전환사채권발행결정)Apr 22, 2026Open on DART
- Rights offering (paid-in capital increase) decision주요사항보고서(유상증자결정)Apr 15, 2026Open on DART
- Convertible bond issue decision주요사항보고서(전환사채권발행결정)Apr 15, 2026Open on DART
- Annual general meeting results정기주주총회결과Mar 31, 2026Open on DART
- Notice on Grant of Stock Purchase Options주식매수선택권부여에관한신고Mar 31, 2026Open on DART
- New Facility Investment, etc.신규시설투자등Mar 20, 2026Open on DART
- Annual report (Dec 2025)사업보고서 (2025.12)Mar 20, 2026Open on DART
- Audit report submitted감사보고서제출Mar 18, 2026Open on DART
- Shareholders' meeting called주주총회소집결의Feb 27, 2026Open on DART
- Reference Document for Proxy Solicitation of Voting Rights의결권대리행사권유참고서류Feb 27, 2026Open on DART
- Notice of shareholders' meeting주주총회소집공고Feb 27, 2026Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항 (Lu-177-DGUL(포큐보타이드 사테트라세탄) 식품의약품안전처 품목 조건부 허가 신청)Dec 30, 2025Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항(임상시험결과) (전이성 거세저항성 전립선암 환자에서 Ga-68-NGUL / Lu-177-DGUL 의 제 1/2 상 임상시험의 최종결과보고서(CSR) 수령)Dec 12, 2025Open on DART
- Determination of Shareholder Register Closure Period or Record Date주주명부폐쇄기간또는기준일설정Dec 12, 2025Open on DART
- Quarterly report (Sep 2025)분기보고서 (2025.09)Nov 14, 2025Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항(임상시험계획승인신청등결정) (전이성 거세 저항성 전립선암 환자에서 Lutetium(177Lu) DGUL(포큐보타이드) 과 Pembrolizumab(키트루다) 병용요법의 제1상 임상시험계획승인(IND))Sep 12, 2025Open on DART
- Investor relations (IR) event기업설명회(IR)개최Sep 9, 2025Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항(임상시험결과) (표준요법에 실패한 전이성 거세저항성 전립선암 환자에서 Lu177DGUL의 국내 임상 제2상 Topline data 수령)Sep 4, 2025Open on DART
- Half-year report (Jun 2025)반기보고서 (2025.06)Aug 13, 2025Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항(임상시험계획승인신청) (전이성 거세 저항성 전립선암 환자에서 Lutetium(177Lu) DGUL 과 Pembrolizumab 병용요법의 제 1상 임상시험계획승인신청(IND))Jun 23, 2025Open on DART
- Quarterly report (Mar 2025)분기보고서 (2025.03)May 13, 2025Open on DART
- Annual general meeting results정기주주총회결과Mar 31, 2025Open on DART
- Report on Appointment, Dismissal, or Mid-Term Resignation of Independent Directors독립이사의선임ㆍ해임또는중도퇴임에관한신고Mar 31, 2025Open on DART
- Notice on Grant of Stock Purchase Options주식매수선택권부여에관한신고Mar 31, 2025Open on DART
- Annual report (Dec 2024)사업보고서 (2024.12)Mar 20, 2025Open on DART
- Audit report submitted감사보고서제출Mar 14, 2025Open on DART
- Investor relations (IR) event기업설명회(IR)개최Mar 11, 2025Open on DART
- Shareholders' meeting called주주총회소집결의Feb 28, 2025Open on DART
- Notice of shareholders' meeting주주총회소집공고Feb 28, 2025Open on DART
- Change in Revenue or Profit/Loss Structure of 30% or More (15% or More for Large Companies)매출액또는손익구조30%(대규모법인은15%)이상변동Jan 31, 2025Open on DART
- Determination of Shareholder Register Closure Period or Record Date주주명부폐쇄기간또는기준일설정Dec 12, 2024Open on DART
- Quarterly report (Sep 2024)분기보고서 (2024.09)Nov 13, 2024Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Nov 11, 2024Open on DART
- 5%+ holding report주식등의대량보유상황보고서(약식)Oct 23, 2024Open on DART
- Amended: Insider shareholding report[기재정정]임원ㆍ주요주주특정증권등소유상황보고서Oct 22, 2024Open on DART
- 5%+ holding report주식등의대량보유상황보고서(일반)Oct 22, 2024Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Oct 22, 2024Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Oct 22, 2024Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Oct 22, 2024Open on DART
- Securities Issuance Results Report증권발행실적보고서Oct 11, 2024Open on DART
- Amended: Prospectus[기재정정]투자설명서Oct 7, 2024Open on DART
- Amended: Prospectus[기재정정]투자설명서Oct 4, 2024Open on DART
Titles in Korean until English translations are added.
Also known as: Cellbion / 셀비온 / 308430 / KRX:308430
Source: KRX statistical information